New technology aims to streamline cancer treatment process.
Leal Health, formerly known as Trialjectory, an AI-powered platform for patient access to advanced cancer treatments, has launched a predictive patient tool designed to help cancer patients navigate their treatment journey at all stages of the disease. Its aim is to educate patients and their oncologists on their treatment options in a timely manner and to remove barriers to care in advance. The goal as well is to enable pharmaceutical companies to better identify potential patients that could match to their trials in the future.
With this technology, Leal’s platform, according to the company, can preemptively match cancer patients with available treatment options that could be relevant for them in the future should their disease progress. At the same time, Leal provides pharma companies and clinical trial sponsors insight into patients who have a high probability of participating in future trials due to their disease state. For example, sponsors can access insight into how minority and underrepresented patients’ cancer changes over time and how patients can adjust current treatments to remain eligible for other clinical trials.
“For most patients, cancer isn’t a one-and-done fight; it’s an ongoing, ever-changing war. Because cancer states change over time, a treatment that might not be relevant for a patient today could become a game changer down the line,” says Tzvia Bader, Co-founder and CEO, Leal Health. “With this offering, patients who fail a treatment can quickly pivot to a new therapy identified by Leal that is appropriate for them, rather than having to start a new search from scratch and waste valuable time that they may not have.”
Reference: Leal Health Launches Industry-First Predictive Patient Journey Offering, NEW YORK, N.Y., May 8, 2023.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.